A practical reference on GHK-Cu: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.
Solid GHK-Cu is generally stored as a dry powder under frozen conditions to limit degradation. The peptide bond can hydrolyze, and the copper center can be displaced by strong chelators such as EDTA. Aqueous solutions are less stable than the solid and may lose color or form precipitates over time. Temperature, pH, and oxygen exposure are the main variables that affect shelf life. Neutral to slightly acidic conditions tend to preserve the complex better than strongly alkaline media.
Routine handling calls for minimizing freeze-thaw cycles and preparing solutions shortly before use. Glass or inert plastic containers reduce adsorption and metal leaching. Working stocks are often kept at 2–8 °C for short periods, while long-term reference material stays at −20 °C or below. Light protection is prudent because prolonged exposure may accelerate oxidation of the peptide. Documentation of lot number, concentration, and preparation date supports reproducibility in laboratory work.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
Discovery of GHK is generally attributed to work in the 1970s that isolated a plasma factor influencing liver cell behavior. Subsequent studies identified the copper-binding tripeptide and its ability to chelate copper with high affinity. Early reports linked the complex to wound healing and tissue remodeling in animal models. The free peptide and the copper-bound form have different properties, so the two are distinguished in the literature. Whether endogenous GHK-Cu serves a single primary physiological role remains an open question.
| Property | Value | Notes |
|---|---|---|
| Physical state | Blue-violet solid | Typically supplied as lyophilized powder |
| Storage temperature | −20 °C or below | Desiccated, protected from light |
| Working stability | Hours to days at 2–8 °C | Depends on concentration and buffer |
| Identity test | RP-HPLC with UV-Vis | Visible absorbance near 600–630 nm |
| Copper assay | ICP-MS or AAS | Metal content confirms stoichiometry |
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Mechanistic accounts focus on how the complex delivers copper and how the released peptide interacts with the extracellular matrix. Copper is an essential cofactor for lysyl oxidase and other enzymes involved in collagen and elastin cross-linking, and GHK is one of several peptides able to carry the metal. Reported effects include altered gene expression in fibroblasts and changes in matrix metalloproteinase activity, although many of these findings come from cell culture rather than whole organisms. The relative contribution of the peptide backbone, the copper ion, and downstream copper metabolism is not fully resolved.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide was first isolated from human albumin in 1973 by Loren Pickart, who later described its copper-binding behavior. Early work linked the complex to wound healing and tissue remodeling. Plasma levels of GHK decline with age, a pattern that stimulated interest in topical and supplemental applications. Researchers have reported that the tripeptide influences collagen synthesis, antioxidant defense, and inflammatory signaling in cell and animal models. Human clinical evidence remains limited and often relies on small studies.
Many described the separation from family members as excruciating, with some children being unable to talk to their parents, living with relatives in Gaza or having to monitor and parent younger siblings while their parents care for their injured siblings. On 16 August 2025, the U.S. State Department announced that it had suspended the issuance of visitor visas to people from the Gaza Strip, including children who require urgent medical care. In January–April 2024, medical evacuations for children from Gaza averaged about 296 per month; by late 2024 the rate had fallen to under one per day. In October 2024, UNICEF said children were dying not only from the violence itself but also because survivors were often unable to leave Gaza for urgent, life-saving treatment. By July/September 2025, an estimated 2,500-4,500 of critically wounded children are waiting for permits to be evacuated for care.
The earliest description and illustration of gigantomastia dates to 1669. In July of that year the Plymouth physician William Durston wrote to the Royal Society, reporting the case of a patient named Elizabeth Travers. Durston's account was soon published in the Society's Philosophical Transactions, and includes the following account of the onset of symptoms:Elizabeth Treves, [sic] 23. or 24. years of age, fair of complexion, brown-hair'd, of an healthy constitution, low of stature, of honest repute, but of mean and poor parentage, near this Town [Plymouth], was on Friday July 3d, 1669 in good health, and went well to bed, where she took as good rest and sleep, as ever before, but in the morning, when she awaken'd, and attempted to turn herself in her bed, was not able, finding her Breasts so swell'd, that she was affrighted to an astonishment. Then endeavoring to sit up, the weight of her Breasts fastned her to her bed; where she hath layn ever since, yet without all pain and weakness either in her Breasts, or in any other part.Durston later wrote to the Society to report that Travers had died on October 21 of the same year, four months after the onset of enlargement. One breast removed after the woman's death weighed 64 lb (29 kg).
Drug carriers: Carriers such as "Trojan horse" molecules, liposomes, and nanoparticles might theoretically allow a therapeutic drug to enter the brain. Such tactics are mostly in the investigatory stages and are not yet clinically relevant to brain tumour treatment.
Sources: en.wikipedia.org
A third ZIPRA incursion attempt in July 1969 met with similarly catastrophic results. Thereafter, ZIPRA abandoned the notion of attempting to infiltrate the country with large groups of insurgents equipped only with small arms; it limited itself to more irregular forms of warfare until it could stockpile enough heavy weaponry to mount a major conventional invasion. For its part, the ZANLA leadership criticised ZIPRA's continued fixation with winning a major conventional engagement, arguing that the failed incursions demonstrated the futility of engaging the Rhodesian military in the type of pitched battles in which it held an indisputable advantage. ZIPRA's failure to obtain support from the locals was also noted, and ZANLA began implementing a long-term covert politicisation programme to cultivate civilian support throughout its future area of operations.
Oglufanide (Glu-Trp, thymogen) is a dipeptide having the sequence L-Glu-L-Trp. It is an immunomodulator and has been investigated for the treatment of hepatitis C. It was originally isolated from calf thymus gland extracts and has been used medicinally in Russia as a component of Thymalin, a mixture of thymus derived peptides and small proteins also containing other components such as thymosins and thymulin. Synthetic versions of Glu-Trp containing unnatural D-amino acids or with gamma-peptide bond links also have different immunomodulatory effects such as the immunosuppressor thymodepressin (D-Glu-D-Trp).
The bioavailability of intranasal fentanyl is about 70–90% but with some imprecision due to clotted nostrils, pharyngeal swallow, and incorrect administration. For both emergency and palliative use, intranasal fentanyl is available in doses of 50, 100, 200, or 400 (PecFent) μg. In emergency medicine, safe administration of intranasal fentanyl with a low rate of side effects and a promising pain-reducing effect was demonstrated in a prospective observational study in about 900 out-of-hospital patients. In children, intranasal fentanyl is useful for the treatment of moderate and severe pain and is well tolerated. Furthermore, a 2017 study suggested the efficacy of fentanyl lozenges in children as young as five, weighing as little as 13 kg. Lozenges are more inclined to be used as the child is in control of sufficient dosage, in contrast to buccal tablets.
=== Liquid Chromatography === High-performance liquid chromatography can be used to separate tRNAs based on aminoacylated tRNA isoacceptors. This method cannot fully separate the tRNA species and cannot distinguish between codons, though it still can find quantitative differences between different cell lines.
Sources: en.wikipedia.org
=== February === February 13, 2013: United Kingdom Sir Mervyn King, Governor of the Bank of England, says he believes "a recovery is in sight". However, he also expects inflation to rise to at least 3% by the summer of 2013 and to remain above the Bank's 2% target for two years.
== History == Much of the preparatory work that led into the adoption of RM-ODP as an ISO standard was carried out by the Advanced Networked Systems Architecture (ANSA) project. This ran from 1984 until 1998 under the leadership of Andrew Herbert (now MD of Microsoft Research in Cambridge), and involved a number of major computing and telecommunication companies. Parts 2 and 3 of the RM-ODP were eventually adopted as ISO standards in 1996. Parts 1 and 4 were adopted in 1998.
Tandem time-of-flight (TOF/TOF) is a tandem mass spectrometry method where two time-of-flight mass spectrometers are used consecutively. To record full spectrum of precursor (parent) ions TOF/TOF operates in MS mode. In this mode, the energy of the pulse laser is chosen slightly above the onset of MALDI for specific matrix in use to ensure the compromise between an ion yield for all the parent ions and reduced fragmentation of the same ions. When operating in a tandem (MS/MS) mode, the laser energy is increased considerably above MALDI threshold. The first TOF mass spectrometer (basically, a flight tube which ends up with the timed ion selector) isolates precursor ions of choice using a velocity filter, typically, of a Bradbury–Nielsen type, and the second TOF-MS (that includes the post accelerator, flight tube, ion mirror, and the ion detector) analyzes the fragment ions. Fragment ions in MALDI TOF/TOF result from decay of precursor ions vibrationally excited above their dissociation level in MALDI source (post source decay ). Additional ion fragmentation implemented in a high-energy collision cell may be added to the system to increase dissociation rate of vibrationally excited precursor ions. Some designs include precursor signal quenchers as a part of second TOF-MS to reduce the instant current load on the ion detector.
A prodrug of epitiostanol, mepitiostane, which is also marketed for the treatment of breast cancer, is reported to show a high rate of virilizing side effects such as acne, hirsutism, and voice changes in women.
== Short-term regulation of hunger and food intake == Short-term regulation of hunger and food intake involves neural signals from the GI tract, blood levels of nutrients, GI tract hormones, and psychological factors.
Sources: en.wikipedia.org
Dry powder is typically stored frozen at −20 °C or lower, protected from moisture and light. Short-term working amounts may be kept refrigerated. Avoiding repeated temperature changes helps preserve the material.
Reversed-phase HPLC with UV-visible detection is common because the copper complex absorbs visible light. Mass spectrometry provides molecular mass confirmation. Copper-specific methods such as ICP-MS quantify the metal content.
The blue color comes from copper-ligand interactions. Displacement of copper by chelators or changes in pH can shift or diminish the color. Such changes often indicate that the complex has been altered.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.